Nintenib 150 mg Capsule is a targeted cancer drug. It is used to treat pulmonary fibrosis in which the cause is not known ( idiopathic pulmonary fibrosis). The chemical formula of this drug is C31H33N5O4. Nintenib 150 mg Capsule is classified as a kinase inhibitor. Nintenib 150 mg Capsule blocks the action of enzymes that cause fibrosis. It is available as an oral capsule form easily taken by mouth.

• Idiopathic pulmonary fibrosis
• Impaired respiratory function
• Interstitial lung disease
• NSCLS ( Non small cell lung Cancer)

Nintenib 150 mg Capsule slows disease progression by reducing the rate of decline in forced vital capacity in those patients who have idiopathic pulmonary fibrosis with mild or moderate lung function impairment.

• Loss of appetite
• Weight loss
• Fatigue
• Headache
• Unhealed wound

• Nausea
• Vomiting
• Diarrhoea
• Stomach upset

• Altered blood pressure
• Liver problems (jaundice)
• Dark brown urine
• Yellowing of the skin
• Lack of energy
• Shortness of breath
• Numbness or weakness
• Difficulty in speech
• Malena ( blood in stool)

Nintenib 150 mg Capsule is available in oral capsule form taken by mouth as directed by your doctor. Take it regularly as advised, frequency and dosage of the medicine will be decided by your doctor as per the severity of disease and certain other factors and how your body responds to the treatment.

Nintenib 150 mg Capsule binds to fibroblast growth factor receptor's intracellular ATP binding pocket, PDGFR (platelet derived growth factor receptor) and VEGFRs ( Vascular growth factor receptors resulting in blockage of the receptors and the downstream signalling cascades.